1283. Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects

BACKGROUND: BRII-778 is a modified release (MR) formulation of rilpivirine for once-weekly (QW) oral administration. BRII-778 aims to prolong oral absorption, lower C(max), relatively, and reduce peak to trough ratio achieved with a MR formulation of rilpivirine, within the known efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Margolis, David A, Ma, Ji, Watkins, Michael, Wang, Yujin, Trivedi, Chetana, Wei, Xuelian, Zhong, Lijie, Patel, Kamlesh, Yan, Li, Hong, Zhi, Girardet, Jean-Luc, Xu, Lianhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752700/
http://dx.doi.org/10.1093/ofid/ofac492.1114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752700/
http://dx.doi.org/10.1093/ofid/ofac492.1114

Ejemplares similares